AI pharmaceutical company InSilico Medicine Cayman TopCo is racing for a Hong Kong IPO, with its core product having received approval from China's CDE to commence Phase III clinical trials

Wallstreetcn
2025.11.11 09:13

Today, AI biotechnology company InSilico Medicine updated its Hong Kong IPO prospectus. In 2024, the company’s revenue is expected to be USD 85.83 million, a year-on-year increase of 67.7%; the adjusted net loss is expected to be USD 22.67 million, significantly narrowing year-on-year. Benefiting from the Series E financing completed in the first half of 2025, the company’s cash and cash equivalents increased from USD 126 million at the end of 2024 to USD 212 million by the end of June 2025.

Its core product ISM001-055 (Rentosertib) has received confirmation from China’s CDE to proceed with Phase III clinical trials after successfully completing Phase IIa studies in China. (Hard AI)

Source: Wallstreetcn The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.